Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alferminogene tadenovec

Drug Profile

Alferminogene tadenovec

Alternative Names: Ad5-FGF4; AdFGF-4; AGT-MI; Angiogenic gene therapy; Cardionovo; FGF-4 angiogenic DNA - Taxus Cardium Pharmaceuticals; FGF-4 gene therapy; Fibroblast growth factor-4 gene therapy - Taxus Cardium Pharmaceuticals; Generx; Generx microvascular therapy; mdFGF-4; mdFGF-4 - Taxus Cardium Pharmaceuticals

Latest Information Update: 10 Feb 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cardium Therapeutics
  • Developer Angionetics; Gene Biotherapeutics; Taxus Cardium Pharmaceuticals Group
  • Class Gene therapies; Growth factors; Ischaemic heart disorder therapies
  • Mechanism of Action Angiogenesis inducing agents; Fibroblast growth factor stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Coronary artery disease; Myocardial ischaemia
  • Discontinued Heart failure

Most Recent Events

  • 07 Feb 2017 Alferminogene tadenovec receives Fast Track designation for Coronary artery disease [Intracoronary,Infusion] in USA
  • 12 Sep 2016 The U.S. FDA Center for Biologics Evaluation and Research approves alferminogene tadenovec for the phase III AFFIRM study in Coronary artery disease and Myocardial ischaemia
  • 11 Jul 2016 Alferminogene tadenovec licensed to an affiliated entity of Huapont Life Sciences in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top